Implantable drug delivery devices, also called as implantable drug eluting devices, allow targeted and localized drug delivery once the device is implanted in the body. There are various implantable drug delivery devices available such as vascular stents, electro stimulation devices, orthopedic devices, and others. An implantable device also delivers drugs to the primary site of action, when it is combined with the drugs. Thus, many drug therapies have been developed for hormonal disorders, cardiovascular disorders, oncology, ophthalmology, and others.
There are two types of drug delivery systems: biodegradable and non-biodegradable. Biodegradable drug-eluting devices (also referred to as bioerodible) use biocompatible materials such as polyesteramide (PEA) and Poly Lactic-co-Glycolic Acid (PLGA) to deliver drugs and once implanted, it decomposes over time. On the other hand, non-biodegradable drug-eluting devices (also referred to as biodurable) use biocompatible materials such as silicone rubber (polydimethylsiloxane or PDMS), polyethylene-vinyl acetate (EVA), and thermoplastic polyurethane (TPU) to deliver drugs. Non-biodegradable drug-eluting devices can be refilled with medication (eg, via injection) and the device’s effects are almost immediately reversible upon removal.
Market Dynamics
Increasing product launches is expected to drive the global implantable drug delivery devices market growth over the forecast period. For instance, in 2019, Occular Therapeutics launched Dextenza ophthalmic insert in the U.S. market. Dextenza ophthalmic insert is an ocular insert that is designed to release 0.4 mg of dexamethasone to relieve pain after ophthalmic surgery. It can deliver drugs for up to 30 days after treatment in a physician’s office.
Companies are engaged in receiving approvals from the regulatory authorities for further marketing the products in the global market. For instance, in 2018, United Therapeutics Corporation received the U.S Food and Drug Administration (FDA) approval for the use of Remodulin (treprostinil) injection in the implantable system. In the Remodulin implantable system, the entire delivery system is implanted into the patient’s body and the system is refilled by healthcare professionals at an interval of up to 16 weeks depending on the prescribed dose, by using a syringe needle and through the patient's skin.
Key features of the study:
- This report provides an in-depth analysis of global implantable drug delivery devices market, provides market size (US$ 12,015.2 Million), and compound annual growth rate (CAGR 7.7 %) for the forecast period (2020 – 2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global implantable drug delivery devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Boston Scientific Corporation, Abbott Laboratories, Medtronic, Merck & Co., Bausch & Lomb Inc., Allergan, Inc., Psivida Corp., Bayer Healthcare, Alimera Sciences, Eyepoint Pharmaceuticals, Valeant Pharmaceuticals, DSM Biomedical, Delpor Inc., Teleflex Incorporated, and 3M Company
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global implantable drug delivery devices market report caters to various stakeholders in this industry including investors, suppliers, implantable drug delivery device manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the implantable drug delivery devices market
Detailed Segmentation:
- Global Implantable Drug Delivery Devices Market, By Product Type:
- Drug infusion pumps
- Intraocular drug delivery devices
- Contraceptive drug delivery devices
- Stents
- Global Implantable Drug Delivery Devices Market, By Technology:
- Biodegradable Implants
- Non-biodegradable Implants
- Global Implantable Drug Delivery Devices Market, By Application:
- Ophthalmology
- Oncology
- Cardiovascular
- Birth control/Contraception
- Others
- Global Implantable Drug Delivery Devices Market, By Region:
- North America
- By Country
- By Product Type:
- Drug infusion pumps
- Intraocular drug delivery devices
- Contraceptive drug delivery devices
- Stents
- By Technology
- Biodegradable Implants
- Non-biodegradable Implants
- By Application
- Ophthalmology
- Oncology
- Cardiovascular
- Birth control/Contraception
- Others
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Product Type:
- Drug infusion pumps
- Intraocular drug delivery devices
- Contraceptive drug delivery devices
- Stents
- By Technology
- Biodegradable Implants
- Non-biodegradable Implants
- By Application
- Ophthalmology
- Oncology
- Cardiovascular
- Birth control/Contraception
- Others
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Product Type:
- Drug infusion pumps
- Intraocular drug delivery devices
- Contraceptive drug delivery devices
- Stents
- By Technology
- Biodegradable Implants
- Non-biodegradable Implants
- By Application
- Ophthalmology
- Oncology
- Cardiovascular
- Birth control/Contraception
- Others
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Product Type:
- Drug infusion pumps
- Intraocular drug delivery devices
- Contraceptive drug delivery devices
- Stents
- By Technology
- Biodegradable Implants
- Non-biodegradable Implants
- By Application
- Ophthalmology
- Oncology
- Cardiovascular
- Birth control/Contraception
- Others
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Product Type:
- Drug infusion pumps
- Intraocular drug delivery devices
- Contraceptive drug delivery devices
- Stents
- By Technology
- Biodegradable Implants
- Non-biodegradable Implants
- By Application
- Ophthalmology
- Oncology
- Cardiovascular
- Birth control/Contraception
- Others
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Product Type:
- Drug infusion pumps
- Intraocular drug delivery devices
- Contraceptive drug delivery devices
- Stents
- By Technology
- Biodegradable Implants
- Non-biodegradable Implants
- By Application
- Ophthalmology
- Oncology
- Cardiovascular
- Birth control/Contraception
- Others
- Company Profiles
- Boston Scientific Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Abbott Laboratories
- Medtronic, Merck & Co.
- Bausch & Lomb Inc.
- Allergan, Inc.
- Bayer Healthcare
- Alimera Sciences
- Eyepoint Pharmaceuticals
- DSM Biomedical
- Delpor Inc.
- Teleflex Incorporated
- 3M Company
“*” marked represents similar segmentation in other categories in the respective section.
